Rib-X initiates Phase II trials for antibiotic compound
The community-acquired pneumonia (CAP) study is a Phase II, multicenter, randomized, double-blind study, which will assess the efficacy of three doses of RX-1741, either once or twice a
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.